Table 2.

IL-2 T cell responses.

Antigen	Gardasil vaccinated CD4/CD154/IL-2 positive T cells Median frequency (IQR)	Number of subjects	p-value	Cervarix vaccinated CD4/CD154/IL-2 positive T cells Median frequency (IQR)	Number of subjects	p-value
HPV6 L1
Baseline	0.000 (0.000–0.003)	14		0.000 (0.000–0.015)	13
7 months	0.080 (0.045–0.130)	13	0.003	0.030 (0.010–0.090)	15	0.028
12 months	0.060 (0.040–0.090)	15	0.001	0.040 (0.010–0.070)	15	0.021
HPV11 L1
Baseline	0.000 (0.000–0.010)	14		0.000 (0.000–0.005)	13
7 months	0.060 (0.030–0.120)	15	0.001	0.020 (0.010–0.110)	15	0.009
12 months	0.050 (0.010–0.090)	15	0.004	0.020 (0.008–0.070)	14	0.007
HPV16 L1
Baseline	0.005 (0.000–0.030)	14		0.010 (0.000–0.020)	15
7 months	0.040 (0.020–0.100)	15	0.004	0.050 (0.010–0.113)	14	0.003
12 months	0.050 (0.020–0.070)	15	0.018	0.030 (0.010–0.050)	15	0.008
HPV18 L1
Baseline	0.000 (0.000–0.003)			0.000 (0.000–0.005)	14
7 months	0.030 (0.010–0.040)	15	0.016	0.040 (0.010–0.070)	15	0.003
12 months	0.020 (0.010–0.050)	15	0.016	0.020 (0.000–0.060)	15	0.108
HPV31 L1
Baseline	0.000 (0.000–0.010)	14		0.000 (0.000–0.020)	15
7 months	0.020 (0.010–0.080)	15	0.013	0.030 (0.010–0.100)	15	0.006
12 months	0.030 (0.000–0.050)	15	0.028	0.030 (0.015–0.075)	13	0.018
HPV45 L1
Baseline	0.000 (0.000–0.020)	14		0.000 (0.000–0.033)	14
7 months	0.020 (0.015–0.035)	13	0.026	0.030 (0.000–0.053)	14	0.325
12 months	0.020 (0.010–0.050)	15	0.011	0.010 (0.000–0.030)	13	0.929